AptaBio Therapeutics Inc.

KOSDAQ:A293780 Stock Report

Market Cap: ₩188.4b

AptaBio Therapeutics Past Earnings Performance

Past criteria checks 0/6

AptaBio Therapeutics's earnings have been declining at an average annual rate of -23.5%, while the Biotechs industry saw earnings growing at 7.2% annually. Revenues have been growing at an average rate of 3919.2% per year.

Key information

-23.5%

Earnings growth rate

-23.5%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate3,919.2%
Return on equity-32.5%
Net Margin-742.9%
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?

Jul 12
Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?

Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money

Mar 26
Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money

Do Institutions Own AptaBio Therapeutics Inc. (KOSDAQ:293780) Shares?

Feb 23
Do Institutions Own AptaBio Therapeutics Inc. (KOSDAQ:293780) Shares?

Companies Like AptaBio Therapeutics (KOSDAQ:293780) Can Afford To Invest In Growth

Jan 01
Companies Like AptaBio Therapeutics (KOSDAQ:293780) Can Afford To Invest In Growth

Revenue & Expenses Breakdown

How AptaBio Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A293780 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 242,055-15,2674,91912,253
31 Mar 24942-11,0122,69314,019
31 Dec 23324-11,8673,91512,380
30 Sep 2353-13,2807,0575,975
31 Dec 2248-10,5652,7886,197

Quality Earnings: A293780 is currently unprofitable.

Growing Profit Margin: A293780 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if A293780's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare A293780's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A293780 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (6.1%).


Return on Equity

High ROE: A293780 has a negative Return on Equity (-32.51%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies